McKesson Co. (NYSE:MCK) Shares Acquired by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC grew its stake in shares of McKesson Co. (NYSE:MCK - Free Report) by 85.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,054 shares of the company's stock after purchasing an additional 1,867 shares during the period. Bryn Mawr Capital Management LLC's holdings in McKesson were worth $2,310,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Synergy Asset Management LLC purchased a new stake in McKesson during the fourth quarter worth about $32,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of McKesson during the 3rd quarter valued at approximately $29,000. Crews Bank & Trust purchased a new stake in shares of McKesson during the 4th quarter worth approximately $33,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of McKesson in the 3rd quarter worth approximately $31,000. Finally, Creative Capital Management Investments LLC purchased a new position in McKesson in the 4th quarter valued at approximately $44,000. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 8,961 shares of McKesson stock in a transaction on Friday, February 14th. The shares were sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the transaction, the chief executive officer now owns 69,625 shares in the company, valued at approximately $41,820,952.50. The trade was a 11.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 579 shares of the company's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $602.81, for a total transaction of $349,026.99. Following the sale, the executive vice president now directly owns 1,443 shares of the company's stock, valued at approximately $869,854.83. This trade represents a 28.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,307 shares of company stock worth $6,177,790. 0.11% of the stock is currently owned by company insiders.

McKesson Price Performance

MCK stock traded down $5.83 on Friday, hitting $597.68. 671,026 shares of the company were exchanged, compared to its average volume of 745,545. The stock has a market capitalization of $74.91 billion, a price-to-earnings ratio of 27.37, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. The business's fifty day moving average is $588.60 and its two-hundred day moving average is $562.48. McKesson Co. has a twelve month low of $464.42 and a twelve month high of $637.51.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts' consensus estimates of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. Equities research analysts expect that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 0.48%. The ex-dividend date is Monday, March 3rd. McKesson's dividend payout ratio is currently 13.00%.

Wall Street Analyst Weigh In

Several analysts have weighed in on MCK shares. Wells Fargo & Company upped their target price on McKesson from $535.00 to $641.00 and gave the company an "equal weight" rating in a report on Friday, December 13th. Evercore ISI increased their price objective on shares of McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. StockNews.com cut shares of McKesson from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th. Bank of America lowered their price target on shares of McKesson from $680.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Finally, Robert W. Baird raised shares of McKesson from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $531.00 to $688.00 in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $645.79.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.